SCHEMBL6462936

SCHEMBL6462936

COc1cc(CN[C@H]2CC[C@@H](Nc3nc4c(c(N(C)C)n3)CCCC4)CC2)cc(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
TSHR P16473 3/20 0.51
L3MBTL1 Q9Y468 4/20 0.45
ADRA2A P08913 2/20 0.42
MCHR1 Q99705 2/20 0.42
KDM4E B2RXH2 3/20 0.40
POLB P06746 2/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CNR1 P21554 1/20 0.39
KCNH2 Q12809 1/20 0.39
AURKB Q96GD4 1/20 0.39
ACHE P22303 4/20 0.38
BCHE P06276 2/20 0.38
LMNA P02545 3/20 0.35
ABCB1 P08183 2/20 0.34
TUBB3 Q13509 2/20 0.34
GAA P10253 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6873997 1.00 ALDH1A1 (0.51) ALDH1A1TSHRL3MBTL1ADRA2AMCHR1
SCHEMBL6879219 0.90 ALDH1A1 (0.55) ALDH1A1TSHRADRA2AMCHR1POLB
SCHEMBL6879216 0.90 ALDH1A1 (0.55) ALDH1A1TSHRADRA2AMCHR1POLB
SCHEMBL6878174 0.90 MCHR1 (0.43) ALDH1A1TSHRL3MBTL1ADRA2AMCHR1
SCHEMBL6466543 0.90 MCHR1 (0.43) ALDH1A1TSHRL3MBTL1ADRA2AMCHR1
SCHEMBL6463847 0.88 MCHR1 (0.42) ALDH1A1TSHRL3MBTL1ADRA2AMCHR1
SCHEMBL6879122 0.88 MCHR1 (0.42) ALDH1A1TSHRL3MBTL1ADRA2AMCHR1
SCHEMBL6875692 0.88 ALDH1A1 (0.52) ALDH1A1ADRA2AMCHR1KDM4EPOLB
SCHEMBL6875695 0.88 ALDH1A1 (0.52) ALDH1A1ADRA2AMCHR1KDM4EPOLB
SCHEMBL6458901 0.87 ALDH1A1 (0.41) ALDH1A1TSHRADRA2AMCHR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US claimed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO claimed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP claimed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 ALDH1A1 2036/4885TSHR 156/4885L3MBTL1 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.